Michael J A Maresh1, Valerie A Holmes2, Christopher C Patterson2, Ian S Young2, Donald W M Pearson3, James D Walker4, David R McCance5. 1. Department of Obstetrics, St. Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom michael.maresh@cmft.nhs.uk. 2. Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom. 3. Department of Diabetes, Aberdeen Royal Infirmary, Aberdeen, United Kingdom. 4. Department of Diabetes, St. John's Hospital at Howden, West Lothian, United Kingdom. 5. Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, United Kingdom.
Abstract
OBJECTIVE: To assess the relationship between second and third trimester glycemic control and adverse outcomes in pregnant women with type 1 diabetes, as uncertainty exists about optimum glycemic targets. RESEARCH DESIGN AND METHODS: Pregnancy outcomes were assessed prospectively in 725 women with type 1 diabetes from the Diabetes and Pre-eclampsia Intervention Trial. HbA1c (A1C) values at 26 and 34 weeks' gestation were categorized into five groups, the lowest, <6.0% (42 mmol/mol), being the reference. Average pre- and postprandial results from an eight-point capillary glucose profile the previous day were categorized into five groups, the lowest (preprandial <5.0 mmol/L and postprandial <6.0 mmol/L) being the reference. RESULTS: An A1C of 6.0-6.4% (42-47 mmol/mol) at 26 weeks' gestation was associated with a significantly increased risk of large for gestational age (LGA) (odds ratio 1.7 [95% CI 1.0-3.0]) and an A1C of 6.5-6.9% (48-52 mmol/mol) with a significantly increased risk of preterm delivery (odds ratio 2.5 [95% CI 1.3-4.8]), pre-eclampsia (4.3 [1.7-10.8]), need for a neonatal glucose infusion (2.9 [1.5-5.6]), and a composite adverse outcome (3.2 [1.3-8.0]). These risks increased progressively with increasing A1C. Results were similar at 34 weeks' gestation. Glucose data showed less consistent trends, although the risk of a composite adverse outcome increased with preprandial glucose levels between 6.0 and 6.9 mmol/L at 34 weeks (3.3 [1.3-8.0]). CONCLUSIONS: LGA increased significantly with an A1C ≥6.0 (42 mmol/mol) at 26 and 34 weeks' gestation and with other adverse outcomes with an A1C ≥6.5% (48 mmol/mol). The data suggest that there is clinical utility in regular measurement of A1C during pregnancy.
OBJECTIVE: To assess the relationship between second and third trimester glycemic control and adverse outcomes in pregnant women with type 1 diabetes, as uncertainty exists about optimum glycemic targets. RESEARCH DESIGN AND METHODS: Pregnancy outcomes were assessed prospectively in 725 women with type 1 diabetes from the Diabetes and Pre-eclampsia Intervention Trial. HbA1c (A1C) values at 26 and 34 weeks' gestation were categorized into five groups, the lowest, <6.0% (42 mmol/mol), being the reference. Average pre- and postprandial results from an eight-point capillary glucose profile the previous day were categorized into five groups, the lowest (preprandial <5.0 mmol/L and postprandial <6.0 mmol/L) being the reference. RESULTS: An A1C of 6.0-6.4% (42-47 mmol/mol) at 26 weeks' gestation was associated with a significantly increased risk of large for gestational age (LGA) (odds ratio 1.7 [95% CI 1.0-3.0]) and an A1C of 6.5-6.9% (48-52 mmol/mol) with a significantly increased risk of preterm delivery (odds ratio 2.5 [95% CI 1.3-4.8]), pre-eclampsia (4.3 [1.7-10.8]), need for a neonatal glucose infusion (2.9 [1.5-5.6]), and a composite adverse outcome (3.2 [1.3-8.0]). These risks increased progressively with increasing A1C. Results were similar at 34 weeks' gestation. Glucose data showed less consistent trends, although the risk of a composite adverse outcome increased with preprandial glucose levels between 6.0 and 6.9 mmol/L at 34 weeks (3.3 [1.3-8.0]). CONCLUSIONS: LGA increased significantly with an A1C ≥6.0 (42 mmol/mol) at 26 and 34 weeks' gestation and with other adverse outcomes with an A1C ≥6.5% (48 mmol/mol). The data suggest that there is clinical utility in regular measurement of A1C during pregnancy.
Authors: Elisa Gualdani; Graziano Di Cianni; Marta Seghieri; Paolo Francesconi; Giuseppe Seghieri Journal: Acta Diabetol Date: 2021-04-09 Impact factor: 4.280
Authors: Miira M Klemetti; Hannele Laivuori; Minna Tikkanen; Mika Nuutila; Vilho Hiilesmaa; Kari Teramo Journal: Diabetologia Date: 2016-01 Impact factor: 10.122
Authors: Marco F Mastroeni; Sandra A Czarnobay; Caroline Kroll; Katherinne B W Figueirêdo; Silmara S B S Mastroeni; Jean C Silva; Mohammad K A Khan; Sarah Loehr; Paul J Veugelers Journal: Matern Child Health J Date: 2017-04
Authors: Grenye O'Malley; Barak Rosenn; Emily V Nosova; Yogish C Kudva; Sophia Scarpelli Shchur; Camilla Levister; Ravinder Kaur; Jordan E Pinsker; Kristin Castorino; Mei Mei Church; Eyal Dassau; Carol J Levy Journal: J Diabetes Sci Technol Date: 2021-07-03
Authors: Julie C Søholm; Marianne Vestgaard; Björg Ásbjörnsdóttir; Nicoline C Do; Berit W Pedersen; Lone Storgaard; Birgitte B Nielsen; Lene Ringholm; Peter Damm; Elisabeth R Mathiesen Journal: Diabetologia Date: 2021-06-19 Impact factor: 10.122